A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers
87801493LYM1001
Phase 1 other active
Quick answer
A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers for Non-Hodgkin Lymphoid Malignancies is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Non-Hodgkin Lymphoid Malignancies
- Phase
- Phase 1
- Modality
- other
- Status
- active